Journal
FEBS JOURNAL
Volume 278, Issue 23, Pages 4683-4700Publisher
WILEY
DOI: 10.1111/j.1742-4658.2011.08182.x
Keywords
antibody conjugates; cancer therapy; intracellular trafficking; moxetumomab pasudotox; Pseudomonas exotoxin A; recombinant immunotoxins
Categories
Funding
- National Institutes of Health, National Cancer Institute, Center for Cancer Research
- MedImmune, LLC
Ask authors/readers for more resources
Pseudomonas exotoxin A (PE) is a highly toxic protein secreted by the opportunistic pathogen Pseudomonas aeruginosa. The modular structure and corresponding mechanism of action of PE make it amenable to extensive modifications that can redirect its potent cytotoxicity from disease to a therapeutic function. In combination with a variety of artificial targeting elements, such as receptor ligands and antibody fragments, PE becomes a selective agent for the elimination of specific cell populations. This review summarizes our current understanding of PE, its intoxication pathway, and the ongoing efforts to convert this toxin into a treatment for cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available